Press enter or spacebar to select a desired language.
Research
Press enter or spacebar to select a desired language.

PubMed COVID-19 Clinical Care

131 - 140 of 1067 results found

One-year follow-up of the immunogenicity and safety of a primary series of the NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults: Final report of a phase I/II randomized controlled trial

Date
Saturday, February 03, 2024 - 4:00 AM
Description
BACKGROUND: In the interim report of this phase I/II randomized, placebo-controlled trial in Japanese adults, a two-dose primary series of NVX-CoV2373 (5 µg SARS-CoV-2 recombinant nanoparticle spike protein [rS]; 50 µg Matrix-M) administered 21 days

On the origins of SARS-CoV-2 main protease inhibitors

Date
Monday, January 29, 2024 - 4:00 AM
Description
In order to address the world-wide health challenge caused by the COVID-19 pandemic, the 3CL protease/SARS-CoV-2 main protease (SARS-CoV-2-M^(pro)) coded by its nsp5 gene became one of the biochemical targets for the design of antiviral drugs. In